Dysregulation of Cyclic AMP and Cyclic PIP Synthesis: Implications for Disease and Advances in Therapeutic Development
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Medicinal Chemistry".
Deadline for manuscript submissions: 25 January 2026 | Viewed by 283
Special Issue Editor
Interests: regulation of metabolism; cyclic AMP and the cyclic AMP antagonist prostaglandylinositol cyclic phosphate (cyclic PIP); the development of type-2 diabetes and hypertension
Special Issue Information
Dear Colleagues,
The reversible phosphorylation of proteins is a key control mechanism that regulates cellular processes such as metabolism, cell division, and neurotransmission. Two intracellular regulators, cyclic AMP and cyclic PIP (prostaglandylinositol cyclic phosphate), control the equilibrium between the phospho- and de-phospho-form of key enzymes and, thus, control the activity of these enzymes. Derailing this equilibrium has serious consequences on the well-being of the human body. A simple example from our everyday life is as follows: We know to take the foot from the gas pedal when we want to stop a car because leaving one foot on the gas pedal and the other foot on the brake will use up the brakes too fast. However, we do not apply this knowledge to our bodies. To be fit enough to handle daily stress overloads, we push our bodies, for instance, by drinking a lot of coffee, to stay in shape, or, in biochemical terms, to prepare for an overload of catabolic processes. Generally, we do not give the body enough time and appropriate conditions for anabolic recovery. Besides from this unhealthy lifestyle, some illnesses can derail these control mechanisms. The dysregulation of protein phosphorylation is known to be related, for instance, to illnesses as Alzheimer’s disease, chronic inflammatory disease, cancer, and type 2 diabetes.
Generally, we divide signal transduction into three levels: First, the receptor to which a hormone or neurotransmitter binds. Second, the synthesis of intracellular regulators, which spread the signal inside the cell. Third, resulting regulatory changes. Illnesses such as hypertension are treated with selective beta-adrenoceptor antagonists; illnesses such as asthma are treated with highly selective beta-adrenoceptor agonists. The treatment of illnesses such as type 2 diabetes is more diverse, since patients are treated either with overloads of insulin or with synthetic drugs with different mechanisms of action. Cancer-related hyperphosphorylation has also been subjected to attempted treatment with synthetic protein kinase A inhibitors.
This Special Issue will invite scientists engaged in these or closely related research fields to contribute their views/results. We aim to combine newer research results related to broken signal transduction in this publication. This will give not only an overview on where we stand presently, but, more importantly, these data will show convincing results suggestive of progress. This progress will provide a means for achieving further success, not only for treating single illnesses but also for multiple illnesses. Insofar as they are related to changes of the synthesis of these two regulators, cyclic AMP or cyclic PIP, improvements in treatments for one of these illnesses may inspire improvements in treatments for comparable illnesses.
Dr. Heinrich K Wasner
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- reversible protein phosphorylation
- cyclic AMP
- cyclic PIP
- signal transduction
- cyclic AMP antagonist
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
